Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Baranyi, A; Meinitzer, A; Putz-Bankuti, C; Stauber, R; Kapfhammer, HP; Rothenhäusler, HB.
Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.
Psychosom Med. 2014; 76(3):197-207
Doi: 10.1097/PSY.0000000000000042
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Baranyi Andreas
- Co-Autor*innen der Med Uni Graz
- Kapfhammer Hans-Peter
- Meinitzer Andreas
- Putz-Bankuti Csilla
- Rothenhäusler Hans-Bernd
- Stauber Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The aim of this study was to examine the association of depressive symptoms with asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Patients with chronic hepatitis C infection were examined during interferon-α (IFN-α) treatment, which is often associated with treatment-induced depression. The associations between IFN-α-induced depressive symptoms with ADMA and SDMA levels were prospectively investigated until 3 months after treatment. Psychiatric and biological assessments were obtained at six different time points: before, during (at 1, 3, 6, and 9 months), and after the end of IFN-α treatment. During IFN-α treatment, 22 (53.7%) patients fulfilled the criteria for a treatment-related depressive disorder at least once during treatment. The increase in ADMA levels from baseline (depression group: 0.63 [0.08] μM, no depression group: 0.69 [0.08] μM) in response to IFN-α treatment was considerably higher in patients with IFN-α treatment-induced depressive episodes compared with patients without treatment-induced depressive episodes (3 months after the start of treatment: depression group: 0.72 [0.08] μM, no depression group: 0.72 [0.11] μM; ADMA: repeated-measure design analysis of variance [time × depression]: F(5,151) = 2.446, p = .036). The increase in SDMA was not associated with treatment-induced depression. Depression in response to IFN-α treatment is associated with elevated ADMA levels. These findings are relevant to nitric oxide-related biological pathways linking depression to increased cardiovascular disease risk. Future studies are needed to clarify the role of serotonin in these pathways and may lead to preventative treatment strategies.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Analysis of Variance -
- Antiviral Agents - adverse effects Antiviral Agents - therapeutic use
- Arginine - analogs & derivatives Arginine - metabolism
- Cardiovascular Diseases - epidemiology Cardiovascular Diseases - metabolism
- Chromatography, Liquid -
- Depression - chemically induced Depression - epidemiology Depression - metabolism
- Depressive Disorder - chemically induced Depressive Disorder - epidemiology Depressive Disorder - metabolism
- Drug Therapy, Combination -
- Female -
- Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - metabolism Hepatitis C, Chronic - psychology
- Humans -
- Interferon-alpha - adverse effects Interferon-alpha - therapeutic use
- Male -
- Nitric Oxide Synthase - antagonists & inhibitors
- Prospective Studies -
- Psychiatric Status Rating Scales - statistics & numerical data
- Regression Analysis -
- Ribavirin - therapeutic use
- Risk Factors -
- Time Factors -
- Find related publications in this database (Keywords)
- hepatitis C
- IFN-alpha
- depression
- asymmetric dimethylarginine
- symmetric dimethylarginine
- cardiovascular risk